PANCREATIC CANCER

This study tested a personalized treatment where a patient's own immune cells were modified in a lab to recognize and attack unique mutations in their cancer. It was designed for people with advanced solid tumors like lung, pancreatic, or ovarian cancer who had not responded to s…

This study tested whether combining two drugs, trametinib and hydroxychloroquine, could help overcome treatment resistance in people with advanced pancreatic cancer that had spread. It involved 20 adults whose cancer had not responded to at least one prior therapy. The goal was t…

This study tested a new drug called NUV-868, alone or with other cancer drugs (olaparib or enzalutamide), in 82 adults with advanced solid tumors like ovarian, pancreatic, prostate, or breast cancer. The main goals were to check safety and find the right dose. The trial was stopp…

This study tested a new therapy where a person's own white blood cells are collected, genetically modified in a lab to recognize a specific cancer mutation (KRAS G12D), and then given back to attack tumors. It involved 5 adults with advanced gastrointestinal, pancreatic, gastric,…

This early-phase study tested a special immune cell treatment called CAR T cells in people with advanced pancreatic cancer that could not be removed by surgery. The goal was to see if the treatment was safe and possible to give, either through a vein or directly into the abdomen.…

This trial tested a new drug called SOT102, alone or with standard chemotherapy, in 31 people with advanced pancreatic cancer. The goal was to find the safest dose and see if it could shrink tumors. However, the study was stopped early because of unexpected safety problems that r…

This study tested the drug niraparib in 22 adults with advanced solid tumors (like breast, lung, or pancreatic cancer) that have a specific genetic change called a PALB2 mutation. The goal was to see if niraparib could shrink tumors or slow their growth. The study was stopped ear…

This study tested a new drug called TAK-500, alone or with pembrolizumab, in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The goal was to check safety and see if the drug could shrink tumors. The trial was terminated early, so results are limited.

This study tested an experimental drug called VLS-101 in people with advanced solid tumors, including breast, lung, stomach, pancreatic, and ovarian cancers that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors. However, the study…

This early-phase study tested an experimental oral drug called IK-595 in 75 adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have specific RAS or RAF gene mutations and no standard treatment options left. The goal was to check the drug's safety…

This study aimed to see if adding the experimental drug BNT321 to standard chemotherapy (mFOLFIRINOX) could help prevent pancreatic cancer from coming back after surgery. It was designed for people whose tumors were completely removed. However, the trial was stopped early after e…

This study tested a new approach for people with locally advanced pancreatic cancer that cannot be removed by surgery. Participants received a radioactive injection directly into the tumor along with standard chemotherapy, aiming to shrink the tumor and control the disease. Only …

This study tested whether adding MR-guided radiation to standard chemotherapy could help control pain in people with metastatic pancreatic cancer. It included 9 adults whose cancer had not worsened after 8 weeks of chemo. The trial was stopped early, so results are limited.

This study looked at genetic mutations in tumors from 565 people with cancers of the liver, bile ducts, gallbladder, pancreas, esophagus, or stomach. The goal was to see how often these mutations occur and whether they can help doctors choose more personalized treatments. The stu…